The Lucy Trial: Legitimizing Using Childhood memory rescripting early in the first Year
- Conditions
- The present study focuses on the treatment of patients with borderline personality disorder.
- Registration Number
- NL-OMON29642
- Lead Sponsor
- o external funding. This study is supported by the participating mental health institutes and the Department of Clinical Psychology, University of Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 73
Borderline PD based on the DSM-5 as primary diagnosis (assessed with SCID-II or SCID-5-P) and a score of 20 or above on the Borderline Personality Disorder Severity index (BPDSI).
- Age 18-65
- Ability to understand, read, write and speak Dutch.
- Alcohol or drug dependence needing clinical detox. (After 3 months of abstinence participation is possible).
- Comorbid psychotic disorder (when > 1 year in full remission inclusion is possible).
- Antisocial personality disorder with a history of physical interpersonal violence in the last two years.
- DSM-5 Bipolar disorder, type 1 (current or past) . If there has been no manic episode the last year patients will be included.
- Acute suicide risk
- IQ < 80
- Schema Therapy of any kind (e.g., individual, group, inpatient, outpatient, day treatment) in the past year.
- Patients should not start with any form of psychological treatment or medication during screening or during the study’s treatment or waitlist period. Medication should be on a stable level for 3 months, if not stopped. (Non-PD focused supportive treatment may be continued during wait and screening, but not during the study treatment and study 1-year follow-up period)
- Not able to plan (group) therapy sessions of 90 minutes and individual sessions of 45-60 minutes once a week during 2 years within the treatment period.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome measure is change in the severity and frequency of the DSM-5 BPD manifestations (BPDSI-IV, total score; Arntz et al., 2003; Giesen-Bloo, Wachters, Schouten, & Arntz, 2010). This outcome measure is frequently used in other studies of ST: Giesen-Bloo et al. (2006), Van Asselt et al. (2008), Nadort et al. (2009), and Wetzelaer et al. (2014). This interview yields dimensional total severity scores, as well as dimensional scores per criterion, and diagnostic status.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.